{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mirelis JG"],"funding":["Instituto de Salud Carlos III"],"pagination":["1183-1196"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9546008"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(7)"],"pubmed_abstract":["Aims
Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM.Methods and results
Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogen"],"journal":["European journal of heart failure"],"pubmed_title":["Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy."],"pmcid":["PMC9546008"],"funding_grant_id":["PI18/0004","PI20/0320","PI19/01283"],"pubmed_authors":["Garcia-Pavia P","Fernandez-Avila A","Casas G","Climent V","Gonzalez-Carrillo J","Palomino-Doza J","Barriales-Villa R","Mogollon-Jimenez MV","Navarro M","Garcia-Granja PE","Espinosa MA","Escobar-Lopez L","Ripoll-Vera T","Brugada R","Pena-Pena ML","Ochoa JP","Garcia-Alvarez A","Gallego-Delgado M","Cabrera-Borrego E","Rodriguez-Gonzalez E","Rodriguez-Palomares JF","Alvarez-Barredo M","Dominguez F","Bayes-Genis A","Garcia-Pinilla JM","Villacorta E","Mora-Ayestaran N","Mirelis JG"],"additional_accession":[]},"is_claimable":false,"name":"Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.","description":"Aims
Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM.Methods and results
Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogen","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-19T04:47:50.325Z","creation":"2025-04-19T04:47:50.325Z"},"accession":"S-EPMC9546008","cross_references":{"pubmed":["35485241"],"doi":["10.1002/ejhf.2514"]}}